FDA Pharmacogenomics Data Guidance To Be Finalized Later This Year
Executive Summary
FDA will not issue a final guidance on pharmacogenomic data submissions until later this year, Center for Drug Evaluation & Research Acting Director Steven Galson, MD, told the Biotechnology Industry Organization annual meeting in San Francisco June 8
You may also be interested in...
FDA Scientific Initiatives Will Not Change After Election, Crawford Predicts
FDA's scientific initiatives will not be affected by the outcome of the Nov. 2 Presidential elections, Acting Commissioner Lester Crawford said Oct. 10 at an R&D conference sponsored by Phacilitate in Geneva, Switzerland
FDA Scientific Initiatives Will Not Change After Election, Crawford Predicts
FDA's scientific initiatives will not be affected by the outcome of the Nov. 2 Presidential elections, Acting Commissioner Lester Crawford said Oct. 10 at an R&D conference sponsored by Phacilitate in Geneva, Switzerland
Computer Simulations Of Clinical Trials To Be Addressed In FDA Guidance
FDA plans to address the use of computer simulation models in an upcoming guidance on issues firms should consider at the end of Phase IIa